Mutant p53 is a bona fide useful biomarker impacting therapy programs such as those for EGFR [e.g., TKI (tyrosine kinase inhibitor)-EGFR] [37], the clinical regimen [38], and a useful biomarker for glioma [66]. This evidence concerns the gene EGFR and central nervous system cancer.